Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story – Simply Wall St

Investor Checklist: How This News Frames Ionis Right Now. Quick Assessment. ⚖️ Price vs Analyst Target: At US$81.15 versus a consensus target of about …